Carregant...
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC)
We report a case using combination cabozantinib plus nivolumab to salvage disease control in a patient with refractory metastatic renal cell carcinoma. The patient had previously experienced disease progression from high‐dose interleukin‐2, sunitinib, pazopanib, cabozantinib, and nivolumab, all give...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930408/ https://ncbi.nlm.nih.gov/pubmed/33251710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13617 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|